
Javier Casas
@vhasili
Uro-oncología, Cirugía mínimamente invasiva (lap, robot y láser), Urología funcional y suelo pélvico.
Apasionado por la tecnología.
ID: 485683289
07-02-2012 13:27:36
128 Tweet
134 Followers
377 Following


👏👏Game changing paper LumenNicolaas🇻🇦 Piet Ost Karel Decaestecker et al, in the Tx of Newly Diagnosed Low-volume MxT PCa. 2-yr OS was 93%, 100%, and 69%, and 2-yr CSS was 93%, 100%, and 75% for radical prostatectomy, radiotherapy, and no local treatment sciencedirect.com/science/articl…



Updated post-ASCO slide on neoadjuvant IO trials in #MIBC. Could we dissect the contribution of SoC chemo in combos? Minimally for pT0, a bit for pT<2. RFS immature but differences not overwhelming. ASCO European Association of Urology (EAU) Global Society of Rare GU Tumors Università Vita-Salute San Raffaele Ospedale San Raffaele



Prognostic Score and Benefit from Abiraterone in First-line mCRPC buff.ly/3ixXIrA David Lorente David Olmos C@silda Ll@cer "This study validated the prognostic value of Armstrong risk model in pts treated w/ 1L ARSIs. Abiraterone provides greater benefit in low-risk pts"










